2019
DOI: 10.1016/j.steroids.2019.108431
|View full text |Cite
|
Sign up to set email alerts
|

Design, synthesis and biological evaluation of new steroidal β-triazoly enones as potent antiproliferative agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
9
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 14 publications
(9 citation statements)
references
References 21 publications
0
9
0
Order By: Relevance
“…The synthesis of the intermediates is shown in Scheme 1 . Compounds 1a–1j were obtained by diazotization and azide reactions of various anilines ( Zhao et al, 2019 ). Then, a click reaction between intermediates 1a–1j and propynol gave compounds 2a–2j ( Luan et al, 2019 ).…”
Section: Resultsmentioning
confidence: 99%
“…The synthesis of the intermediates is shown in Scheme 1 . Compounds 1a–1j were obtained by diazotization and azide reactions of various anilines ( Zhao et al, 2019 ). Then, a click reaction between intermediates 1a–1j and propynol gave compounds 2a–2j ( Luan et al, 2019 ).…”
Section: Resultsmentioning
confidence: 99%
“…In 2019, Huang et al 44 reported the synthesis of a series of novel steroidal β-triazolyl enones using the CuAAC click reaction and Claisen-Schmidt condensation reaction as the key steps. These new derivatives were further evaluated for their antiproliferative activity.…”
Section: Scheme 8 Synthesis Of Derivatives 24a and 24bmentioning
confidence: 99%
“…During the development of new inhibitors of CYP17A1, a large number of androstane and pregnane derivatives have been introduced containing pyridyl-, picolidine-, pyrazolyl-, imidazolyl-, triazolyl-, isoxazolinyl-, dihydrooxazolinyl-, tetrahydrooxazolinyl-, benzimidazolyl-, and carbamoyl- substituents, mainly in positions 16, 17, and 22 [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ]. Galeterone, the most advanced among them and having a multiple mechanism of action, has reached phase III clinical trials [ 19 ].…”
Section: Introductionmentioning
confidence: 99%